<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894994</url>
  </required_header>
  <id_info>
    <org_study_id>FLX475-03</org_study_id>
    <nct_id>NCT04894994</nct_id>
  </id_info>
  <brief_title>FLX475 in Combination With Ipilimumab in Advanced Melanoma</brief_title>
  <official_title>Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAPT Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAPT Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of&#xD;
      FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated&#xD;
      with an anti-PD-1 or anti-PD-L1 agent.&#xD;
&#xD;
      The study will be conducted starting with a safety run-in portion in which 6 eligible&#xD;
      subjects will be enrolled and treated for at least one 3-week cycle to determine if the&#xD;
      safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately&#xD;
      20-subject study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of FLX475 in combination with ipilimumab measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0, including dose-limiting toxicities and serious adverse events.</measure>
    <time_frame>Approximately 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate in subjects treated with FLX475 in combination with ipilimumab</measure>
    <time_frame>Through study completion (approximately 2 years)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Melanoma</condition>
  <arm_group>
    <arm_group_label>FLX475 and ipilimumab combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLX475</intervention_name>
    <description>Tablet</description>
    <arm_group_label>FLX475 and ipilimumab combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>FLX475 and ipilimumab combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage IV or unresectable Stage III advanced melanoma&#xD;
&#xD;
          -  Prior treatment with at least 2 months of anti-PD-(L)1 agent&#xD;
&#xD;
          -  Measurable disease at baseline&#xD;
&#xD;
          -  Tumor available for biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy or severe hypersensitivity to biologic agents&#xD;
&#xD;
          -  History of Grade 3-4 immune-related adverse events leading to discontinuation of prior&#xD;
             immunotherapy&#xD;
&#xD;
          -  Prior treatment with ipilimumab or other CTLA-4 antagonists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Ho, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>RAPT Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>650-489-9019</phone>
    <email>clinical.trials@rapt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Seja</last_name>
      <phone>310-794-6892</phone>
      <email>eseja@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Colon-Colon</last_name>
      <email>marjorie.coloncolon@moffitt.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Talcott</last_name>
      <phone>314-273-0656</phone>
      <email>wu-grayson@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Simpson</last_name>
      <phone>713-792-2921</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Immunological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

